What lymphatic drainage tools can and can't do for your health

Influencers swear by lymphatic drainage to allegedly reduce puffiness, contour their faces and bodies, and boost overall ...

Agenus reports response rate in colon cancer trial

Agenus ( AGEN) reported that 72% of patients with locally advanced colon cancer had no detectable cancer remaining at surgery ...
BIOENGINEER

Review Finds Fungal Compounds Promising, but Skin-Cancer Trials Remain Limited

A review finds that fungal compounds can suppress tumour growth, alter immunity and limit metastasis in skin-cancer models, ...

Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS …

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced early Phase 2 results from the mismatch ...
University College London (UCL)

Breast cancer gene test could save NHS millions of pounds a year

A gene test which can identify which patients with low-risk breast cancer need chemotherapy could save the NHS around £4 ...
BIOENGINEER

Invisible wounds: Faroese breast cancer survivors describe life after treatment

A qualitative study of seven Faroese breast cancer survivors reveals how fatigue, emotional rupture at discharge, identity ...

Libtayo® (cemiplimab) Longer-Term Data Show Increasing and Clinically Meaningful Overall Survival Benefit with Adjuvant Treatment in High-Risk Cutaneous Squamous Cell ...

Longer-term data reflecting nearly 4 years of follow-up show a further reduction in the risk of death from 14% to 37% for those initially treated with Libtayo, despite an 88% crossover from the ...
quiverquant

Regeneron Reports Nearly Four-Year C-POST Data Show Sustained Survival Benefit for Adjuvant Libtayo in High-Risk CSCC

U.S. FDA-approved Indications Libtayo is a prescription medicine used to treat: ...